DrugPatentWatch Database Preview
Drugs in Development Information for CC-220
Email this page to a colleague
What is the development status for investigational drug CC-220?
CC-220 is an investigational drug.
There have been 16 clinical trials for CC-220.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2014.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Emory University.
There are twenty-nine US patents protecting this investigational drug and two hundred and thirty-eight international patents.
Summary for CC-220
| US Patents | 29 |
| International Patents | 238 |
| US Patent Applications | 99 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 1 (2014-11-01) |
| Vendors | 20 |
Recent Clinical Trials for CC-220
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | Celgene | Phase 1/Phase 2 |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphom | Celgene | Phase 1 |
| Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma | Celgene | Phase 1/Phase 2 |
Clinical Trial Summary for CC-220
Top disease conditions for CC-220
Top clinical trial sponsors for CC-220
US Patents for CC-220
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CC-220 | Try Before You Buy | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | Celgene Corporation (Summit, NJ) | Try Before You Buy |
| CC-220 | Try Before You Buy | Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione | Celgene Corporation (Summit, NJ) | Try Before You Buy |
| CC-220 | Try Before You Buy | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | Celgene Corporation (Summit, NJ) | Try Before You Buy |
| CC-220 | Try Before You Buy | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | Celgene Corporation (Summit, NJ) | Try Before You Buy |
| CC-220 | Try Before You Buy | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus | Celgene Corporation (Summit, NJ) | Try Before You Buy |
| CC-220 | Try Before You Buy | Apremilast for the treatment of a liver disease or a liver function abnormality | Celgene Corporation (Summit, NJ) | Try Before You Buy |
| CC-220 | Try Before You Buy | Antiproliferative compounds and methods of use thereof | Celgene Corporation (Summit, NJ) | Try Before You Buy |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CC-220
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CC-220 | Australia | AU2015305449 | 2034-08-22 | Try Before You Buy |
| CC-220 | Brazil | BR112017003620 | 2034-08-22 | Try Before You Buy |
| CC-220 | Canada | CA2958867 | 2034-08-22 | Try Before You Buy |
| CC-220 | Chile | CL2017000416 | 2034-08-22 | Try Before You Buy |
| CC-220 | China | CN107073115 | 2034-08-22 | Try Before You Buy |
| CC-220 | Eurasian Patent Organization | EA201790439 | 2034-08-22 | Try Before You Buy |
| CC-220 | European Patent Office | EP3182996 | 2034-08-22 | Try Before You Buy |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
